Noxafil Approved for Treatment of Oropharyngeal Candidiasis

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 11
Volume 15
Issue 11

The FDA has approved Schering-Plough's novel triazole antifungal agent Noxafil (posaconazole) Oral Suspension for the treatment of oropharyngeal candidiasis, including infections refractory to itraconazole and/or fluconazole.

ROCKVILLE, Maryland--TheFDA has approved Schering-Plough'snovel triazole antifungal agent Noxafil(posaconazole) Oral Suspension for thetreatment of oropharyngeal candidiasis,including infections refractory to itraconazoleand/or fluconazole. The drugrecently received FDA approval for theprevention of invasive Aspergillus andCandida infections in patients 13 years ofage and older who are at high risk ofdeveloping these infections due to beingseverely immunocompromised, such ashematopoietic cell transplant recipientswith graft-vs-host disease or those withhematological malignancies with prolongedneutropenia from chemotherapy(see ONI October 2006, page 1).

The FDA approval of Noxafil for treatingoropharyngeal candidiasis is basedprimarily on the results of a randomized,controlled, evaluator-blinded clinicalstudy in HIV-infected patients that comparedNoxafil with fluconazole, as well asa noncomparative study of Noxafil inHIV-infected patients with oropharyngealcandidiasis refractory to treatmentwith fluconazole or itraconazole.

Recent Videos
Experts from Vanderbilt University Medical Center emphasize gathering a second opinion to determine if a tumor is resectable in patients with pancreatic cancer.
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Experts from Vanderbilt University Medical Center discuss the use of intraoperative radiation therapy in a 64-year-old patient with pancreatic cancer.
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Related Content